{"id":"68ga-psma-11","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5095039","moleculeType":"Small molecule","molecularWeight":"1029.92"},"_fixedAt":"2026-03-30T18:10:14.298154","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"68Ga-PSMA-11 consists of gallium-68 (a positron-emitting radioisotope) conjugated to a small molecule ligand that targets PSMA, a transmembrane protein highly expressed on prostate cancer cells. When injected intravenously, the agent accumulates at sites of PSMA expression, allowing PET imaging to detect and localize prostate cancer lesions, including metastases. This enables improved staging, restaging, and treatment planning in prostate cancer patients.","oneSentence":"68Ga-PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable visualization and detection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:01.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of PSMA-positive lesions in prostate cancer patients for staging and restaging"}]},"_fixedFields":["pubmed(236)"],"trialDetails":[{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":"Prostatic Neoplasms","enrollment":469},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT04987086","phase":"NA","title":"68Ga-PSMA PET in the Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-06-01","conditions":"Renal Cancer, Metastases, PSMA PET","enrollment":300},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT07455097","phase":"","title":"COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2026-01-01","conditions":"Intermediate-risk Prostate Cancer, High-risk Prostate Cancer","enrollment":600},{"nctId":"NCT06004661","phase":"PHASE2","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-04","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":20},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT07089550","phase":"","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-04-02","conditions":"PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic","enrollment":1300},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04506567","phase":"PHASE1, PHASE2","title":"Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-08-18","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":62},{"nctId":"NCT05160597","phase":"EARLY_PHASE1","title":"Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-01-13","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT05176223","phase":"PHASE2","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-01-30","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":29},{"nctId":"NCT04946370","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-08-12","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT07381582","phase":"EARLY_PHASE1","title":"Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT07365397","phase":"NA","title":"Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-19","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT07357259","phase":"NA","title":"Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-02-03","conditions":"High-risk Prostate Cancer","enrollment":244},{"nctId":"NCT06444412","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-12","conditions":"WHO Grade 3 Glioma, WHO Grade 4 Glioma","enrollment":25},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":69},{"nctId":"NCT06353321","phase":"","title":"Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-12-12","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT04777071","phase":"PHASE2","title":"An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-05-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":141},{"nctId":"NCT07324733","phase":"NA","title":"Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Primary Sjögren Syndrome, PET","enrollment":60},{"nctId":"NCT05562791","phase":"PHASE1","title":"A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-28","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT06450548","phase":"NA","title":"Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA","status":"RECRUITING","sponsor":"Centre Henri Becquerel","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic","enrollment":60},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT06881823","phase":"PHASE1, PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT07301827","phase":"NA","title":"Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Renal Cell Carcinoma","enrollment":66},{"nctId":"NCT05983198","phase":"PHASE1, PHASE2","title":"Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-07","conditions":"Prostate Cancer","enrollment":29},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":"Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":107},{"nctId":"NCT04176497","phase":"PHASE2","title":"PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-07-16","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT06209567","phase":"EARLY_PHASE1","title":"A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-01-05","conditions":"High-grade Glioma, Brain Metastases, Brain Metastases, Adult","enrollment":11},{"nctId":"NCT07242014","phase":"NA","title":"68Ga-XACP3 PET/CT in Prostate Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-09-01","conditions":"Prostate Cancer, PET/CT, ACP3","enrollment":60},{"nctId":"NCT05079698","phase":"PHASE1","title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-01","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT06062745","phase":"PHASE1","title":"Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-01","conditions":"Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT07223034","phase":"PHASE1","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-27","conditions":"Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype","enrollment":20},{"nctId":"NCT04762888","phase":"PHASE2","title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-02-24","conditions":"Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT04838613","phase":"PHASE3","title":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-30","conditions":"Prostatic Neoplasms, Prostate Cancer, Recurrence","enrollment":190},{"nctId":"NCT04631601","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-01-15","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":65},{"nctId":"NCT06999837","phase":"NA","title":"[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-09-23","conditions":"HCC - Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07209878","phase":"PHASE2, PHASE3","title":"68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2020-01-10","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":100},{"nctId":"NCT06265272","phase":"","title":"Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-10","conditions":"Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension","enrollment":45},{"nctId":"NCT06852820","phase":"PHASE2","title":"68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Melissa Lumish","startDate":"2025-09-22","conditions":"Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer","enrollment":10},{"nctId":"NCT05324332","phase":"NA","title":"68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-15","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT03042468","phase":"PHASE1, PHASE2","title":"Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07168616","phase":"","title":"Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2025-09-01","conditions":"Low Risk Prostate Cancer, Clinically Significant Prostate Cancer","enrollment":201},{"nctId":"NCT04745871","phase":"NA","title":"Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2021-05-20","conditions":"Prostate Cancer","enrollment":159},{"nctId":"NCT06521775","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-08-12","conditions":"Metastatic Adenoid Cystic Carcinoma","enrollment":6},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":236},{"nctId":"NCT07052214","phase":"PHASE3","title":"PSMA PET Combined With MRI for the Detection of PCa","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-08-18","conditions":"PCA, Prostate Cancer, Prostatic Neoplasm","enrollment":204},{"nctId":"NCT04030338","phase":"","title":"Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-19","conditions":"Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma","enrollment":58},{"nctId":"NCT04951817","phase":"NA","title":"68Ga-PSMA PET/CT for Ra223 Assessment","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-02","conditions":"Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT04576871","phase":"EARLY_PHASE1","title":"Re-treatment 225Ac-J591 for mCRPC","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-29","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT06359717","phase":"","title":"Prospective Validation of PSMA-RADS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2023-01-01","conditions":"Cancer Prostate","enrollment":477},{"nctId":"NCT04147494","phase":"EARLY_PHASE1","title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-11-05","conditions":"Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma","enrollment":29},{"nctId":"NCT07117760","phase":"PHASE1, PHASE2","title":"Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-04-22","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT05137561","phase":"PHASE2, PHASE3","title":"Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-25","conditions":"Prostate Cancer, Prostate Neoplasm","enrollment":217},{"nctId":"NCT05581979","phase":"","title":"PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2022-01-26","conditions":"Salivary Gland Tumor, Rare Malignant Neoplasm","enrollment":4},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":163},{"nctId":"NCT06059469","phase":"PHASE2","title":"PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2022-05-30","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":20},{"nctId":"NCT06268418","phase":"","title":"Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-30","conditions":"Radionucleide Therapy","enrollment":46},{"nctId":"NCT06067269","phase":"PHASE2","title":"Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-03-28","conditions":"Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8","enrollment":95},{"nctId":"NCT06655064","phase":"","title":"Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-01-30","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":120},{"nctId":"NCT07056790","phase":"PHASE1, PHASE2","title":"Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-05-15","conditions":"Prostate CA","enrollment":40},{"nctId":"NCT06659926","phase":"NA","title":"The Radium-select Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-02-24","conditions":"mCRPC, Male Urogenital Diseases","enrollment":60},{"nctId":"NCT06560905","phase":"PHASE2","title":"Preoperative Planning With PSMA-PET in Melanoma Surgery Trial","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2025-03-11","conditions":"Malignant Melanoma","enrollment":16},{"nctId":"NCT04886986","phase":"PHASE1, PHASE2","title":"Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-06-30","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT05644080","phase":"NA","title":"68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma","status":"RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2023-03-28","conditions":"High Grade Glioma","enrollment":10},{"nctId":"NCT06419348","phase":"EARLY_PHASE1","title":"99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2024-05-20","conditions":"Prostate Cancer Stage, PSMA, SPECT","enrollment":30},{"nctId":"NCT03490838","phase":"PHASE1","title":"177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Advanced Accelerator Applications","startDate":"2018-05-24","conditions":"Prostatic Neoplasm","enrollment":27},{"nctId":"NCT03582774","phase":"PHASE3","title":"Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-12","conditions":"Recurrent Prostate Carcinoma","enrollment":193},{"nctId":"NCT04484701","phase":"","title":"[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2021-02-01","conditions":"Prostatic Neoplasm, Prostatic Cancer","enrollment":1574},{"nctId":"NCT05582876","phase":"NA","title":"Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2023-01-10","conditions":"Prostate Cancer","enrollment":366},{"nctId":"NCT03822845","phase":"PHASE2, PHASE3","title":"Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Michael Graham PhD, MD","startDate":"2019-03-01","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant","enrollment":6},{"nctId":"NCT03768349","phase":"EARLY_PHASE1","title":"PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-01-03","conditions":"Prostate Cancer","enrollment":250},{"nctId":"NCT06907641","phase":"PHASE2","title":"Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2024-11-21","conditions":"Prostate Cancer (Post Prostatectomy)","enrollment":50},{"nctId":"NCT06901492","phase":"NA","title":"The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-06-01","conditions":"PSMA PET/CT, Prostate Cancer, MpMRI","enrollment":120},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT04794777","phase":"PHASE3","title":"Comparing \"Salvage\" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer","status":"RECRUITING","sponsor":"Stefan Carlsson","startDate":"2018-10-30","conditions":"Prostate Cancer","enrollment":450},{"nctId":"NCT04832958","phase":"PHASE2","title":"Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2021-05-15","conditions":"Prostate Cancer","enrollment":81},{"nctId":"NCT06044857","phase":"PHASE1","title":"PSMA PET Response Guided SabR in High Risk Pca","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-07","conditions":"Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT06866782","phase":"","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Fundacio Puigvert","startDate":"2024-09-17","conditions":"Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)","enrollment":600},{"nctId":"NCT06460454","phase":"","title":"PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06461689","phase":"","title":"Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-12-31","conditions":"Prostate Cancer Metastatic","enrollment":80},{"nctId":"NCT05214820","phase":"PHASE2","title":"68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2022-01-17","conditions":"Upper Digestive Tract Cancer","enrollment":20},{"nctId":"NCT06835244","phase":"","title":"Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms","status":"ENROLLING_BY_INVITATION","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2021-09-17","conditions":"PSMA Positive Tumors or Tumor Tissues, Cancer","enrollment":1000},{"nctId":"NCT06242119","phase":"","title":"Clinical Application of the J-PET Scanner Prototype","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2024-03-07","conditions":"Prostate Cancer, Prostatic Hyperplasia, Prostatic Neoplasms","enrollment":25},{"nctId":"NCT05680675","phase":"NA","title":"Dual-Tracer Theranostic PET","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-12-08","conditions":"Neuroendocrine Tumors, Prostate Cancer","enrollment":50},{"nctId":"NCT03465579","phase":"NA","title":"Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2018-05-23","conditions":"68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer","enrollment":261},{"nctId":"NCT04750473","phase":"PHASE1","title":"Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma","enrollment":20},{"nctId":"NCT06770478","phase":"NA","title":"A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-18","conditions":"Tumour of Epithelial Origin, 68Ga-MY6349","enrollment":40},{"nctId":"NCT06769893","phase":"NA","title":"A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-06-12","conditions":"RCC, Renal Cell Cancer","enrollment":60},{"nctId":"NCT02920229","phase":"NA","title":"68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2015-11","conditions":"68Ga-PSMA HBED-PET/CT, Prostate Cancer","enrollment":1230},{"nctId":"NCT03453528","phase":"NA","title":"Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-07-04","conditions":"Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors","enrollment":1225},{"nctId":"NCT03454750","phase":"PHASE2","title":"Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2022-10-25","conditions":"Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":236,"recentPublications":[{"date":"2026","pmid":"41907591","title":"Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.","journal":"Frontiers in oncology"},{"date":"2026 Mar 2","pmid":"41827740","title":"Cost Analysis of PSMA-PET in the PROSPET-BX Trial.","journal":"Cancers"},{"date":"2026 Mar 12","pmid":"41818667","title":"99mTc-HYNIC-PSMA-11 Whole-Body SPECT/CT: A Clinically Viable Alternative to 68Ga-PSMA PET/CT in patients with Prostate Cancer.","journal":"The British journal of radiology"},{"date":"2026 Mar 5","pmid":"41784782","title":"[(68)Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX).","journal":"European journal of nuclear medicine and molecular imaging"},{"date":"2026 Mar 3","pmid":"41774421","title":"Predictive value of the (68)Ga-PSMA-11 PET/CT PRIMARY score for pathological upgrading in patients with ISUP Grade 1 prostate cancer and PSA < 20 ng/mL undergoing radical prostatectomy.","journal":"Annals of nuclear medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["68Ga-PSMA-HBED-CC","68Ga-PSMA-11 injection","Illucix","gallium Ga 68 Gozetotide","68-gallium prostate-specific membrane antigen 11 positron emission tomography/magnetic resonance imaging"],"phase":"phase_3","status":"active","brandName":"68Ga-PSMA-11","genericName":"68Ga-PSMA-11","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"68Ga-PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable visualization and detection. Used for PET imaging of PSMA-positive lesions in prostate cancer patients for staging and restaging.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}